AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update

Current Rheumatology Reports

Volumn 18, Issue 10, 2016, Pages

  Barbhaiya, Medha ^a   Andrade, Danieli ^b   Erkan, Doruk ^c,d   on behalf of APS ACTION, ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Weill Cornell Medicine ^*

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; APS ACTION; Clinical trial

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; HYDROXYCHLOROQUINE; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLACEBO; PROTEIN C; RIVAROXABAN; WARFARIN; ANTIRHEUMATIC AGENT;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CEREBROVASCULAR ACCIDENT; CLINICAL DATA REPOSITORY; CLINICAL RESEARCH; DEEP VEIN THROMBOSIS; DISEASE REGISTRY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; INTERNATIONAL COOPERATION; PREECLAMPSIA; PREVALENCE; REVIEW; THROMBOSIS; THROMBOSIS PREVENTION; CLINICAL TRIAL (TOPIC); COMPLICATION; IMMUNOLOGY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYCHLOROQUINE; THROMBOSIS;

EID: 84988360290     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-016-0611-y     Document Type: Review

References (26)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
2. Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus. 2010;19(4):424–7.
3. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19(4):508–12.
4. Piette JC, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y. The catastrophic antiphospholipid syndrome—Asherson’s syndrome. Annales Med Interne. 2003;154(4):195–6.
5. Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, et al. Antiphospholipid Syndrome Clinical Research Task Force report. Lupus. 2011;20(2):219–24.
6. Erkan D, Pierangeli SS, Lockshin MD. Task Force Report on Antiphospholipid Syndrome Clinical Research. In: Erkan D, Pierangeli SS, editors. Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies. Boston: Springer US; 2012. p. 247–57.
7. Erkan D, Lockshin MD. APS ACTION—AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus. 2012;21(7):695–8.
8. Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
9. Erkan D, Andrade D, Tektonidou M, Fortin P, Ugarte A, Banzato A, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository Initial Analysis. Arthritis Rheum. 2014;66(11):S1253–4. abstract.
10. Erkan D, Zuily S, Banzato A, De Ceulaer K, Cohen H, Tektonidou M, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository (“Registry”) Prospective Follow-up Analysis: one-year first and recurrent thrombosis risk [abstract]. Arthritis Rheumatol. 2015(67): (suppl 10). http://acrabstracts.org/abstract/antiphospholipid-syndrome-alliance-for-clinical-trials-and-international-networking-clinical-database-and-repository-registry-prospective-follow-up-analysis-one-year-first-and-recurrent-thrombosi/. Accessed 18 August 2016.
11. Zuily S, Chighizola CB, Wahl D, Meroni PL, Erkan D. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). http://acrabstracts.org/abstract/antiphospholipid-syndrome-alliance-forclinical-trials-and-international-networking-clinical-database-and-repository-cluster-analysis-identificationof-different-clinical-phenotypes-among-antiphospho/. Accessed 18 August 2016.
12. Ramires de Jesus G, Zuily S, Erkan D, Levy RA. Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Clinical Database and Repository Analysis: Determinants of Thrombosis in Patients Presenting with Obstetric APS [abstract]. Arthritis Rheumatol. 2015;67 (suppl 10). http://acrabstracts.org/abstract/antiphospholipid-syndrome-alliance-for-clinical-trials-internationalnetworking-clinical-database-and-repository-analysis-determinants-of-thrombosis-in-patients-presentingwith-obstetric-aps/. Accessed 18 August 2016.
13. Zuily S, Andrade D, Erkan D, Tektonidou M, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS Action) Clinical Database and Repository Analysis: The Impact of Systemic Lupus Erythematosus on The Clinical Phenotype of Antiphospholipid Antibody-Positive Patients [abstract]. Ann Rheum Dis 2016;75:Suppl 2 548–549.
14. Bertolaccini ML, Andrade D, Lakos G, Willis R, Pengo V, Banzato A, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratory Validation Exercise: Comparison of Enzyme-Linked Immunosorbant Assay (ELISA) and Chemiluminescence Immunoassay (CIA) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/antiphospholipid-syndrome-alliance-for-clinical-trials-and-internationalnetworking-aps-action-core-laboratory-validation-exercise-comparison-of-enzyme-linked-immunosorbantassay-elisa-and-c/. Accessed 18 August 2016.
15. Mackie I, Pengo V, Gray E, Andrade D, Krilis S, Willis R, et al. Antiphospholipid syndrome alliance for clinical trials and international networking (APS action) core laboratory validation exercise: an international performance assessment of lupus anticoagulant (LA) tests using standardised methods and reagents. J Thromb Hem. 2015;13(Suppl2):777.
16. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, de Jesus GR, Erkan D. The estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis. Arthritis Care Res (Hoboken). 2013;65(11):1869–73.
17. Chighizola CB, Andreoli L, de Jesus GR, Banzato A, Pons-Estel GJ, Erkan D. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus. 2015;24(9):980–4.
18. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827–32.
19. Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res. 2011;128(1):77–85.
20. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheum. 2006;33(11):2214–21.
21. Chighizola C, Andreoli L, Banzato A, de Jesus G, Pons-Estel G, Erkan D, et al. The association between antiphospolipid antibodies and related clinical outcomes: a critical review of the literature. Arthritis Rheum. 2013;65(10):S1129.
22. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—a meta-analysis. Lupus. 1997;6(5):467–73.
23. Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998;7(1):15–22.
24. Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 2015;74(11):2028–33.
25. Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Hemost. 2014;12:1801–9.
26. Zuily S, Regnault V, Guillemin F, Kaminsky P, Rat AC, Lecompte T, et al. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res. 2013;132(1):e1–7.